Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences Inc (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company pioneering therapies targeting lipid-signaling pathways, including innovative approaches to cancer support care and neuropathic pain management. This page provides investors and researchers with verified updates on the company’s progress in developing novel treatments for conditions with high unmet medical needs.
Access comprehensive coverage of clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection includes press releases about Artelo’s proprietary cocrystal technology, FABP5 inhibitor program, and advancements in cannabinoid-based therapeutics – all essential for tracking the company’s pipeline evolution.
Stay informed about critical updates including Phase trial results, intellectual property filings, and collaborations with global research institutions. Bookmark this page for real-time insights into how Artelo Biosciences is advancing treatments for chemotherapy-induced neuropathy, cancer-related anorexia, and inflammatory conditions through cutting-edge science.
Artelo Biosciences (NASDAQ: ARTL) has announced that Lead Medicinal Chemist Myles Osborn will present at the 4th ACE Drug Discovery Summit in London on April 3, 2025. The presentation, scheduled for 12:30pm BST, will focus on analyzing multiple datasets regarding Fatty Acid Binding Protein 5 (FABP5) inhibition across various disease models.
The presentation, titled 'Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications,' will explore how FABP5 inhibition affects cellular communication pathways. Research has shown promising activity in treating neuropathic pain, osteoarthritis, cancer, and cancer bone pain.
The company's lead FABP5 inhibitor, ART26.12, is currently in Phase 1 Single Ascending Dose study with healthy volunteers, with data expected in Q2 2025.
Artelo Biosciences (NASDAQ: ARTL) has provided its fiscal 2024 year-end results and business update, highlighting multiple upcoming clinical milestones in 2025. The company reported a net loss of $9.8 million ($3.05 per share) for 2024, compared to $9.3 million in 2023.
Key financial metrics include R&D expenses of $6.0 million (up from $5.7M in 2023), G&A expenses of $4.1 million (down from $4.2M), and cash/investments position of $2.3 million as of December 31, 2024.
Three major clinical programs are advancing:
- ART26.12 (FABP5 inhibitor) Phase 1 study completion expected in Q2 2025
- ART27.13 Phase 2 CAReS trial for cancer anorexia with initial data due by Q2 2025
- ART12.11 (CBD-TMP cocrystal) targeting anxiety and depression, set for human trials in 2H 2025
Artelo Biosciences (NASDAQ: ARTL) has announced new nonclinical results for ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings, presented at the International Medical Cannabis Conference in Switzerland, demonstrated that ART12.11 tablets achieved CBD and metabolite exposure levels similar or greater to equivalent doses of Epidiolex®, the only FDA-approved CBD therapy.
The company's tablet formulations, containing 100mg of CBD, show potential advantages including improved stability, easier dosing, lower cost-of-goods, and enhanced patient adherence. The cocrystallization approach addresses CBD's physical property challenges, enabling the manufacture of simple compression tablets with high drug loading. These results support ART12.11's potential as an alternative CBD formulation with improved pharmacokinetics and enhanced efficacy in nonclinical studies.
Artelo Biosciences (Nasdaq: ARTL) has announced its upcoming presentation at the International Medical Cannabis Conference (IMCCB-25) in Bern, Switzerland, scheduled for February 13-14, 2025. The company will present new data comparing their proprietary ART12.11 tablets to Epidiolex.
Professor Saoirse O'Sullivan, Vice President Translational Science at Artelo, will deliver a presentation titled 'A Cannabidiol Cocrystal (ART12.11) Tablet Has Comparable Pharmacokinetics to Epidiolex' on February 14, 2025. The presentation will focus on recent pharmacokinetic results from canine studies comparing ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), with Epidiolex.
Artelo Biosciences specializes in modulating lipid-signaling pathways to develop treatments for cancer, pain, and dermatological or neurological conditions.
Artelo Biosciences (Nasdaq: ARTL) announced the successful completion of the first cohort in its Phase 1 study of ART26.12, a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. This marks a significant milestone in developing FABP inhibitors as a novel treatment approach for various conditions including cancer, pain, and neuropathies.
The study involved eight healthy volunteers, with the initial safety review completed. ART26.12 is the first-ever selective FABP5 inhibitor to enter clinical trials, targeting an intracellular protein involved in lipid signaling. This mechanism shows promise for managing painful neuropathies non-opioid treatments.
Preclinical studies have shown significant promise in models of Chemotherapy Induced Peripheral Neuropathy (CIPN), Diabetic Neuropathy, cancer bone pain, and osteoarthritis. Encouraged by the preclinical safety profile, Artelo aims to provide initial safety, pharmacokinetic, and biomarker data in the first half of 2025.
The next cohort in the Phase 1 study will offer further insights into the development of ART26.12. The results will help determine suitable doses for a multiple ascending dose study planned for the second half of 2025.
Artelo Biosciences (ARTL) presented Phase 1 data from the CAReS trial for ART27.13, their investigational drug for cancer-related anorexia. The trial demonstrated promising results with two-thirds of participants showing stabilized or reversed weight loss after one month of treatment. The drug was well-tolerated with only mild to moderate adverse events in a minority of participants, with no serious adverse events recorded.
The Phase 2 portion of the trial is currently enrolling participants across fifteen sites in five countries, administering 650 microgram doses with planned escalation up to 1300 micrograms daily. The study will evaluate endpoints including lean body mass, weight gain, quality of life, and safety, with completion expected in the first half of 2025.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 7th Cannabinoid-Derived Drug Development Summit, taking place November 18-20, 2024, in Boston. Professor Saoirse O'Sullivan, VP of Translational Sciences, will present key data from three development programs:
1. FABP5 Inhibitors as Novel Therapeutics (ART26.12)
2. ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia
3. ART12.11: A Novel Cannabidiol Cocrystal comparable to Epidiolex®
The presentations aim to explore business development and collaboration opportunities, showcasing how lipid modification can address serious medical conditions with treatment options.
Artelo Biosciences (ARTL) presented new data on ART26.12, their lead clinical Fatty Acid Binding Protein 5 (FABP5) inhibitor, for osteoarthritis (OA) pain treatment. In preclinical studies at Stony Brook University, ART26.12 showed superior symptom relief compared to naproxen in a surgical rodent OA model, demonstrating significant improvement in weight-bearing across all tested doses. The compound exhibited a clear dose-response relationship, with higher concentrations providing better pain relief.
The FDA has cleared ART26.12 for its first-in-human Phase 1 single ascending dose study, with initial results expected in H1 2025. The treatment targets over 500 million people globally affected by OA, according to WHO, and represents a potential alternative to NSAIDs and opioids.
Artelo Biosciences (NASDAQ: ARTL) reported Q3 2024 financial results and provided updates on its clinical pipeline. The company ended the quarter with $4.9 million in cash and investments. Net loss was $1.1 million ($0.35 per share), compared to $2.4 million in Q3 2023. R&D expenses decreased to $0.3 million from $1.6 million year-over-year. The company received $1.3 million in R&D tax credits from the UK government.
Multiple clinical readouts are expected over the next 15 months. The Phase 2 CAReS trial for ART27.13 in cancer-related anorexia is expected to complete enrollment in early 2025. FDA clearance was received for ART26.12 trials in chemotherapy-induced peripheral neuropathy, with Phase 1 results expected in H1 2025. ART12.11 clinical trials for anxiety and depression are planned for 2025.
Artelo Biosciences (Nasdaq: ARTL) announced that its lead clinical FABP inhibitor, ART26.12, has been accepted into the NIH's Preclinical Screening Platform for Pain (PSPP) program, part of the HEAL Initiative. The PSPP program evaluates non-opioid assets in preclinical pain models and is open to researchers globally. The HEAL Initiative aims to address the overdose epidemic and pain crisis by improving prevention, treatment strategies, and pain management. Artelo previously received FDA clearance for first-in-human studies of ART26.12, with initial results expected in the first half of 2025.
